Webinar: The New Era of Small Molecule Drug Discovery
The webinar on August 18 at 4pm BST/11am EDT, featuring Haydn Boehm—an experienced organic chemist and life science industry leader—will address the challenges in small molecule drug discovery and demonstrate strategies to reduce risks, costs, and time to accelerate therapeutic breakthroughs.
With the renaissance of Small Molecule Drug Discovery, the race to explore uncharted biologically active chemical space is on. However, the process of discovery has multiple challenges that have an impact on time, cost, and risk to any biotech working towards a therapeutic breakthrough.
Join us for our webinar on 18 August at 4pm BST/11am EDT, where we will highlight the challenges and show how to remove these avoidable risks, costs, and time to accelerate your path to discovery.
Featured Speaker
Haydn Boehm
Haydn is focused on helping the life science and drug discovery industries learn how to harmonize their science and data, and accelerate innovation to make the world a healthier, cleaner, better place to live. Haydn has 20 years sales and marketing leadership experience in the life science industry working with companies such as ThermoFisher Scientific, Johnson Matthey, and more recently with Merck KGaA’s Connected Lab Program. Haydn has a PhD in Organic Chemistry from the University of Nottingham, UK, and lives on the Jurassic Coast in Devon, UK with his family.
Event Details
- Date: August 18
- Time: 4pm BST / 11am EDT
Related
Webinar: How to profit from recent innovations in small molecule drug discovery
The webinar, led by Dotmatics’ Director of Product Marketing Haydn Boehm on September 29 at 14:00 BST, will explore the resurgence and innovation in small molecule drug discovery, addressing current research landscapes, challenges, and strategies for optimizing data integration and workflows to accelerate drug candidate identification and reduce costs.
Webinar: Are you Ready for the Renaissance in Small Molecule Drug Discovery?
The webinar titled "Are you Ready for the Renaissance in Small Molecule Drug Discovery?" scheduled for February 2, 2023, features expert Haydn Boehm discussing challenges in small molecule drug discovery, emphasizing the importance of research collaboration, efficient data integration from multiple sources, and workflow optimization to reduce costs and accelerate finding better therapeutic candidates.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
From Fragmented Data to Unified Discovery: LifeArc's Approach to Multimodal R&D
LifeArc, a UK-based medical charity focused on transformative life science, has developed a collaborative, multidisciplinary R&D approach that integrates diverse data from over 100 internal scientists, external pharma, biotech, academic partners, and CROs across multiple therapeutic modalities—including small molecules and biologics like engineered antibodies—to streamline drug discovery and design for diseases such as cancer, Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and COVID-19, enabling unified data flow and informed, data-driven decision-making that has already resulted in four licensed medications and several drugs in trials.
Lessons Learned for AI in Small Molecule Drug Discovery
The article discusses the longstanding use of machine learning in small molecule drug discovery, highlights the recent surge of AI-driven start-ups amid industry hype, and emphasizes the need to temper expectations by learning from past technology challenges and other industries to successfully implement AI in drug discovery.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.